1-7 of 11     Next


Welcome to Volume 3, Third issue, of Everyday Urology - Oncology Insights. In this issue, the applicability and utility of SpaceOAR® Hydrogel will be reviewed as well as the trials that led to its regulatory approval. SpaceOAR was designed as a means of diminishing rectal radiation toxicity. With a phase III trial reporting a decrease in acute and long-term rectal toxicity, as well as an enhanced patient, reported quality of life outcomes, SpaceOAR is quickly being adopted as a component of prostate cancer radiotherapy. 

Welcome to Volume 3, Issue 2 of Everyday Urology – Oncology Insights. This edition’s cover story by Phillip Koo, MD, Imaging Controversies for Localized and Advanced Prostate Cancer explores the challenging topic of imaging modalities for Prostate Cancer. He discusses the use of multiparametric magnetic resonance imaging (mpMRI) as well as positron emission tomography-computed tomography (PET/CT), C-11 Choline, and 18F-Fluciclovine for both localized and advanced prostate cancer disease management. Dr. Koo also reviews the ability of scoring systems, such as the Prostate Imaging Reporting and Data System (PIRADS) as well as similar tools to enhance stratification assessments and interdisciplinary communication.

Welcome to the first issue of the 2018: Everyday Urology- Oncology Insights. The start of the year has ushered in significant advancements and therapeutic approvals for GU oncology management. Along with these recent developments presented at the 2018 ASCO GU meeting, we anticipate additional and important presentations at upcoming major meetings. 
Welcome to Issue 4 of Everyday Urology - Oncology Insights.  This month, Evan Yu, M.D. and Sumanta (Monty) Kumar Pal, M.D. will review and analyze the impact of current clinical trials on patient care, as described by the cover article, The Importance of Clinical Trials for Genitourinary Malignancies. Drs. Yu and Pal will address numerous and important key clinical questions embracing four main genitourinary malignancies: prostate, bladder/urothelial, renal and testicular germ cell cancers, explaining that if not for the dedication of researchers, investigators, and patients (trial subjects) who collectively dedicate their energies to clinical trials, we would not have the evidence-based information which results in regulatory approval and subsequent US and global access for life-prolonging therapies for the genitourinary cancers we diagnose and manage.
Welcome to Issue 3 of Everyday Urology - Oncology Insights which focuses on the exceptionally rapid and groundbreaking advances in both advanced prostate and bladder cancer evaluation and management. 

Petros Grivas’ cover article, Updates on Immunotherapy for Urothelial Cancer, not only succinctly reviews the five new approved immuno-oncology therapies (IO), aka checkpoint (PD pathway) inhibitors and their milestone clinical trials, but also offers guidance regarding treatment selection strategy as well as IO selection within the context of chemotherapeutic options.  Additionally, he discusses a basis for monitoring efficacy of response, potential biomarkers and genomic markers predictive of patient benefit and also reviews the ongoing possibilities for combination strategies. Clearly, both advanced bladder and kidney cancer care information and subsequent
Optimizing the patient clinical outcome (prolonging survival, preserving quality of life, and preventing complications) while avoiding excessive healthcare economic burden is tantamount to the overall improvement of the healthcare system.  Certainly, combining an integrative, multidisciplinary approach, which can attain these aforementioned goals will align with the “Triple Aim”, which proposes that improving the U.S. health care system requires simultaneous pursuit of three aims: improving the experience of care, improving the health of populations, and reducing per capita costs of health care.  

Our first issue of 2017 emphasizes a well-known, yet an evolving and important, theme: optimizing the successful multidisciplinary collaboration amongst oncologic physicians; and furthermore, the importance of patient involvement, also known as, patient-physician shared decision making (and assuredly, successful integrated care).  This multidimensional approach to decision making and treatment has numerous advantages in all phases of the patient care experience, the physician expectation of successful genitourinary oncology outcomes, and efficiency for the healthcare ecosystem.  The authors of our three featured articles in this issue include the specialties of: urology, cardiology and nuclear medicine.


1-7 of 11     Next

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe